OT
Bexxar from GlaxoSmithKline and Zevalin from Biogen Idec. The drugs are approved as a third-line treatment for non-Hodgkin's lymphoma, a form of cancer that begins in the lymph system, after other treatments have failed. But they are sometimes administered as a first line of attack, a use that is not approved. The medications cost $22,210 for a single dose, which constitutes a full course of treatment, according to spokeswomen for both companies. …
lymphomation.org
Having seen a relative go through the modern, conventional treatment for non-Hodkin's lymphoma, yes, everytime. Use the best, new treatment. Al spent one year in treatment, 12 weeks in the hospital. And contracted a serious infection during the course. Assuming $400 per day in the hospital the conventional treatment ran $34K just for the bed. So, yeah, one shot, one week sounds real good. Anytime you spend time in the hospital the risk of unpleasant problems skyrockets.
Given the choice of one shot or one year, which would you pick?
On topic, um, they own a house in LA? |
